FilingReader Intelligence
Kissei Pharmaceutical swings to loss despite 12bn yen asset sale
July 29, 2025 at 12:09 PM UTC•By FilingReader AI
Kissei Pharmaceutical revised its fiscal 2026 operating profit forecast to a 4bn yen loss, down from previous guidance, due to a 10bn yen increase in R&D expenses from a new technology licensing agreement.
However, the company expects to record an extraordinary gain of approximately 12bn yen from selling investment securities, allowing it to maintain its full-year profit forecast of 12.3bn yen.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Notice regarding revision of financial forecasts and recording of extraordinary incomeJuly 29, 2025 at 06:30 AM UTC
Consolidated Financial Results for the Three Months Ended June 30, 2025 [Japanese GAAP]July 29, 2025 at 06:30 AM UTC
Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary IncomeJuly 29, 2025 at 06:30 AM UTC
Supplementary materials for the first quarter financial results for the fiscal year ending March 2026July 29, 2025 at 06:30 AM UTC
Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2025July 29, 2025 at 06:30 AM UTC
TSE:4547•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Kissei Pharmaceutical publishes news
Free account required • Unsubscribe anytime